Dana consortium on HIV dementia begins with study of Otsuka's OPC-14117.
DANA HIV DEMENTIA CONSORTIUM STUDYING OTSUKA's OPC-14117 in the first trial to be undertaken by the Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. The initial trial uses Otsuka Pharmaceutical's OPC-14117 under an IND held by investigator Karl Kieburtz, MD, University of Rochester. Otsuka is donating drug and placebo and allowed cross referencing of its DMF and IND; the agreement is not licensure and Otsuka retains rights to further development.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth